354 related articles for article (PubMed ID: 31816078)
1. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint.
Leipe J; Mariette X
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii49-vii58. PubMed ID: 31816078
[TBL] [Abstract][Full Text] [Related]
2. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy.
Abdel-Wahab N; Suarez-Almazor ME
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii40-vii48. PubMed ID: 31816084
[TBL] [Abstract][Full Text] [Related]
3. Toxicities associated with checkpoint inhibitors-an overview.
Spiers L; Coupe N; Payne M
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii7-vii16. PubMed ID: 31816085
[TBL] [Abstract][Full Text] [Related]
4. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
Cappelli LC; Gutierrez AK; Bingham CO; Shah AA
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1751-1763. PubMed ID: 27998041
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-induced Inflammatory Arthritis: Current Approaches to Management.
Singh N; Shahane A; Sparks JA; Bitoun S; Cappelli LC
Rheum Dis Clin North Am; 2024 May; 50(2):269-279. PubMed ID: 38670725
[TBL] [Abstract][Full Text] [Related]
6. Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.
Abdel-Wahab N; Suarez-Almazor ME
Expert Rev Clin Immunol; 2024 Mar; ():1-21. PubMed ID: 38400840
[TBL] [Abstract][Full Text] [Related]
7. Impact of Non-steroidal Anti-inflammatory Drugs, Glucocorticoids, and Disease-Modifying Anti-Rheumatic Drugs on Cancer Response to Immune Checkpoint Inhibitor Therapy.
Chan KK; Bass AR
Rheum Dis Clin North Am; 2024 May; 50(2):337-357. PubMed ID: 38670731
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?
Chatzidionysiou K; Liapi M; Tsakonas G; Gunnarsson I; Catrina A
Clin Rheumatol; 2021 May; 40(5):1687-1695. PubMed ID: 32989505
[TBL] [Abstract][Full Text] [Related]
9. Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.
Cappelli LC; Shah AA; Bingham CO
Rheum Dis Clin North Am; 2017 Feb; 43(1):65-78. PubMed ID: 27890174
[TBL] [Abstract][Full Text] [Related]
10. Identification of outcome domains in immune checkpoint inhibitor-induced inflammatory arthritis and polymyalgia rheumatica: A scoping review by the OMERACT irAE working group.
Ghosh N; Couette N; van Binsbergen WH; Weinmann SC; Jivanelli B; Shea B; Bass AR; Benesova K; Bingham CO; Calabrese C; Cappelli LC; Chan KK; Choy E; Daoussis D; Goodman S; Hudson M; Jamal S; Leipe J; Lopez-Olivo MA; Suarez-Almazor M; van der Laken CJ; Meara AS; Liew D; Kostine M
Semin Arthritis Rheum; 2023 Feb; 58():152110. PubMed ID: 36372016
[TBL] [Abstract][Full Text] [Related]
11. Treatment of rheumatic adverse events of cancer immunotherapy.
Reid P; Cappelli LC
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101805. PubMed ID: 36539321
[TBL] [Abstract][Full Text] [Related]
12. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events.
Ladouceur A; Ezdoglian A; Sparks JA; Hudson M; Jamal S; Clifford A; Roberts J; Ye C
Rheum Dis Clin North Am; 2024 May; 50(2):181-199. PubMed ID: 38670720
[TBL] [Abstract][Full Text] [Related]
13. De novo Connective Tissue Disorders as Immune-related Adverse Events.
Cho LK; Jamal S
Rheum Dis Clin North Am; 2024 May; 50(2):301-312. PubMed ID: 38670728
[TBL] [Abstract][Full Text] [Related]
14. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis.
Zhang S; Zhou Z; Wang L; Li M; Zhang F; Zeng X
Ther Adv Chronic Dis; 2021; 12():2040622320976996. PubMed ID: 33633822
[TBL] [Abstract][Full Text] [Related]
15. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors.
Ibraheim H; Perucha E; Powell N
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii17-vii28. PubMed ID: 31816081
[TBL] [Abstract][Full Text] [Related]
16. Rheumatologic immune checkpoint inhibitor-related adverse events.
Defoe M; Bermas BL
Curr Opin Rheumatol; 2023 May; 35(3):141-148. PubMed ID: 36912045
[TBL] [Abstract][Full Text] [Related]
17. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Hamad L; Kim S; Lacouture ME; LeBoeuf NR; Lenihan D; Onofrei C; Shannon V; Sharma R; Silk AW; Skondra D; Suarez-Almazor ME; Wang Y; Wiley K; Kaufman HL; Ernstoff MS;
J Immunother Cancer; 2017 Nov; 5(1):95. PubMed ID: 29162153
[TBL] [Abstract][Full Text] [Related]
18. Patient Voices in Rheumatic Immune-related Adverse Events.
Corps KN; Terry O; Lopez-Olivo MA
Rheum Dis Clin North Am; 2024 May; 50(2):241-254. PubMed ID: 38670723
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors: A Systematic Literature Review.
Ghosh N; Chan KK; Jivanelli B; Bass AR
J Clin Rheumatol; 2022 Mar; 28(2):e498-e505. PubMed ID: 34371516
[TBL] [Abstract][Full Text] [Related]
20. Imaging in Rheumatic Immune-related Adverse Events.
Zhang J; Ni R; Oke I; Calabrese C; Strouse J; Weinmann S; Ladouceur A
Rheum Dis Clin North Am; 2024 May; 50(2):313-323. PubMed ID: 38670729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
